{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:06:04Z","timestamp":1794542764376,"version":"4.9.1"},"reference-count":52,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Acute respiratory failure (ARF) is a common cause of admission to intensive care units (ICUs). Mucoactive agents are medications that promote mucus clearance and are frequently administered in patients with ARF, despite a lack of evidence to underpin clinical decision making. The aim of this systematic review was to determine if the use of mucoactive agents in patients with ARF improves clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched electronic and grey literature (January 2020). Two reviewers independently screened, selected, extracted data and quality assessed studies. We included trials of adults receiving ventilatory support for ARF and involving at least one mucoactive agent compared with placebo or standard care. Outcomes included duration of mechanical ventilation. Meta-analysis was undertaken using random-effects modelling and certainty of the evidence was assessed using Grades of Recommendation, Assessment, Development and Evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirteen randomised controlled trials were included (1712 patients), investigating four different mucoactive agents. Mucoactive agents showed no effect on duration of mechanical ventilation (seven trials, mean difference (MD) \u22121.34, 95% CI \u22122.97 to 0.29, I\n                      <jats:sup>2<\/jats:sup>\n                      =82%, very low certainty) or mortality, hospital stay and ventilator-free days. There was an effect on reducing ICU length of stay in the mucoactive agent groups (10 trials, MD \u22123.22, 95% CI \u22125.49 to \u22120.96, I\n                      <jats:sup>2<\/jats:sup>\n                      =89%, very low certainty).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings do not support the use of mucoactive agents in critically ill patients with ARF. The existing evidence is of low quality. High-quality randomised controlled trials are needed to determine the role of specific mucoactive agents in critically ill patients with ARF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42018095408.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thoraxjnl-2019-214355","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T17:20:04Z","timestamp":1591636804000},"page":"623-631","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Mucoactive agents for acute respiratory failure in the critically ill: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1957-5336","authenticated-orcid":false,"given":"Rohan","family":"Anand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronagh","family":"Blackwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"ONeill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwen","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Borthwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Shyamsundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Warburton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David van","family":"Meenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy M","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"2020100610200619000_75.8.623.1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210109"},{"key":"2020100610200619000_75.8.623.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.5669"},{"key":"2020100610200619000_75.8.623.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0291"},{"key":"2020100610200619000_75.8.623.4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.chest.2017.06.039","article-title":"Update in management of severe hypoxemic respiratory failure","volume":"152","author":"Narendra","year":"2017","journal-title":"Chest"},{"key":"2020100610200619000_75.8.623.5","unstructured":"Harrison D . Number of mechanically ventilated patients during 2012 The Intensive Care National Audit & Research Centre (ICNARC), 2014."},{"key":"2020100610200619000_75.8.623.6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.1.237"},{"key":"2020100610200619000_75.8.623.7","first-page":"FC01","article-title":"Prescribing patterns of drugs in acute respiratory distress syndrome (ARDS): an observational study","volume":"9","author":"Magazine","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"2020100610200619000_75.8.623.8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/2229-5151.114272","article-title":"Frequency of hypoxic events in patients on a mechanical ventilator","volume":"3","author":"Mahmood","year":"2013","journal-title":"Int J Crit Illn Inj Sci"},{"key":"2020100610200619000_75.8.623.9","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00003510"},{"key":"2020100610200619000_75.8.623.10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1258\/JRSM.2011.S11101","article-title":"Mechanisms and applications of hypertonic saline","volume":"104 Suppl 1","author":"Elkins","year":"2011","journal-title":"J R Soc Med"},{"key":"2020100610200619000_75.8.623.11","unstructured":"NICE Guidance 2018 . Available: https:\/\/www.nice.org.uk\/guidance [Accessed 20 Mar 2018]."},{"key":"2020100610200619000_75.8.623.12","first-page":"ii","article-title":"BTS\/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults","volume":"71 Suppl 2","author":"Davidson","year":"2016","journal-title":"Thorax"},{"key":"2020100610200619000_75.8.623.13","unstructured":"The Faculty of Intensive Care Medicine . Guidelines for the provision of intensive care services. 2nd Edn. The Faculty of Intensive Care Medicine, 2019."},{"key":"2020100610200619000_75.8.623.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-013-2872-5"},{"key":"2020100610200619000_75.8.623.15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1399-6576.2009.01957.x","article-title":"A Scandinavian survey of drug administration through inhalation, suctioning and recruitment maneuvers in mechanically ventilated patients","volume":"53","author":"Grivans","year":"2009","journal-title":"Acta Anaesthesiol Scand"},{"key":"2020100610200619000_75.8.623.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-015-4114-5"},{"key":"2020100610200619000_75.8.623.17","doi-asserted-by":"crossref","unstructured":"Borthwick M , McAuley D , Warburton J , et al . Mucoactive agent use in adult UK Critical Care Units: a survey of health care professionals\u2019 perception, pharmacists\u2019 description of practice, and point prevalence of mucoactive use in invasively mechanically ventilated patients. PeerJ 2020;8:e8828. doi:10.7717\/peerj.8828","DOI":"10.7717\/peerj.8828"},{"key":"2020100610200619000_75.8.623.18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tacc.2017.12.001","article-title":"High flow nasal oxygen therapy in adult anaesthesia","volume":"18","author":"Millette","year":"2018","journal-title":"Trends in Anaesthesia and Critical Care"},{"key":"2020100610200619000_75.8.623.19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/17476348.2017.1359090","article-title":"The role of mucoactive agents in the mechanically ventilated patient: a review of the literature","volume":"11","author":"Icard","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"2020100610200619000_75.8.623.20","doi-asserted-by":"publisher","DOI":"10.1177\/1753465812437563"},{"key":"2020100610200619000_75.8.623.21","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/CCM.0000000000003904","article-title":"A core outcome set for critical care ventilation trials","volume":"47","author":"Blackwood","year":"2019","journal-title":"Crit Care Med"},{"key":"2020100610200619000_75.8.623.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2020100610200619000_75.8.623.23","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1097\/CCM.0000000000001631","article-title":"Different mortality time points in critical care trials: current practice and influence on effect estimates in meta-analyses","volume":"44","author":"Roth","year":"2016","journal-title":"Crit Care Med"},{"key":"2020100610200619000_75.8.623.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2020100610200619000_75.8.623.25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135"},{"key":"2020100610200619000_75.8.623.26","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jama.2018.0949","article-title":"Effect of on-demand vs routine nebulization of acetylcysteine with salbutamol on Ventilator-Free days in intensive care unit patients receiving invasive ventilation: a randomized clinical trial","volume":"319","author":"van Meenen","year":"2018","journal-title":"JAMA"},{"key":"2020100610200619000_75.8.623.27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/9781119536604.ch10","volume-title":"Cochrane Handbook for systematic reviews of interventions","volume":"23","author":"Deeks","year":"2019"},{"key":"2020100610200619000_75.8.623.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"2020100610200619000_75.8.623.29","first-page":"74","article-title":"Role of hypertonic saline nebulization therapy in patients with early acute respiratory distress syndrome","volume":"5","author":"Dahruog","year":"2017","journal-title":"Intensive Care Med Exp"},{"key":"2020100610200619000_75.8.623.30","first-page":"309","article-title":"Evaluation of the effect of nebulized N-acetylcysteine on respiratory secretions in mechanically ventilated patients: randomized clinical trial","volume":"40","author":"Masoompour","year":"2015","journal-title":"Iran J Med Sci"},{"key":"2020100610200619000_75.8.623.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0883-9441(97)90029-0"},{"key":"2020100610200619000_75.8.623.32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.1.190"},{"key":"2020100610200619000_75.8.623.33","doi-asserted-by":"publisher","DOI":"10.1378\/chest.112.1.164"},{"key":"2020100610200619000_75.8.623.34","first-page":"S233","article-title":"Effect of high dose ambroxol on the extra-vascular lung water and oxygenation of patients with extra-pulmonary acute respiratory distress syndrome","volume":"40","author":"Yong-Jun","year":"2014","journal-title":"Intensive Care Med"},{"key":"2020100610200619000_75.8.623.35","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199207000-00004"},{"key":"2020100610200619000_75.8.623.36","doi-asserted-by":"publisher","DOI":"10.1097\/00024382-200013010-00003"},{"key":"2020100610200619000_75.8.623.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.09.013"},{"key":"2020100610200619000_75.8.623.38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jcrc.2016.04.005","article-title":"Is inhaled prophylactic heparin useful for prevention and management of pneumonia in ventilated ICU patients?: the IPHIVAP Investigators of the Australian and New Zealand intensive care Society clinical Trials Group","volume":"34","author":"Bandeshe","year":"2016","journal-title":"J Crit Care"},{"key":"2020100610200619000_75.8.623.39","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4103\/ejb.ejb_24_17","article-title":"Does nebulized heparin have value in acute respiratory distress syndrome patients in the setting of polytrauma?","volume":"11","author":"Saleh","year":"2017","journal-title":"Egypt J Bronchol"},{"key":"2020100610200619000_75.8.623.40","doi-asserted-by":"publisher","DOI":"10.1186\/cc9286"},{"key":"2020100610200619000_75.8.623.41","unstructured":"ClinicalTrials.gov . N-Acetyl-Cysteine in early acute respiratory distress syndrome. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03346681 [Accessed 12 Jun 2018]."},{"key":"2020100610200619000_75.8.623.42","unstructured":"ClinicalTrials.gov . Inhaled dornase alpha to reduce respiratory failure after severe trauma. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03368092"},{"key":"2020100610200619000_75.8.623.43","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.04086"},{"key":"2020100610200619000_75.8.623.44","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.04165"},{"key":"2020100610200619000_75.8.623.45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60869-7"},{"key":"2020100610200619000_75.8.623.46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001127.pub3"},{"key":"2020100610200619000_75.8.623.47","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.5.1329"},{"key":"2020100610200619000_75.8.623.48","unstructured":"ClinicalTrials.gov . Inhaled dornase alpha to reduce respiratory failure after severe trauma, 2017. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03368092 [Accessed 8 Mar 2019]."},{"key":"2020100610200619000_75.8.623.49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.hrtlng.2018.09.010","article-title":"Mucoactive agents for adults with acute lung conditions: a systematic review","volume":"48","author":"Tarrant","year":"2019","journal-title":"Heart Lung"},{"key":"2020100610200619000_75.8.623.50","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/1024907918794559","article-title":"N-Acetylcysteine for adults with acute respiratory distress syndrome: a meta-analysis of randomized controlled trials","volume":"26","author":"Lu","year":"2019","journal-title":"Hong Kong Journal of Emergency Medicine"},{"key":"2020100610200619000_75.8.623.51","unstructured":"ClinicalTrials.gov . N-Acetyl-Cysteine in early acute respiratory distress syndrome, 2017. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03346681 [Accessed 8 Mar 2019]."},{"key":"2020100610200619000_75.8.623.52","unstructured":"Borthwick M , Shyamsundar M , Warburton J . Mucoactive agents in acute respiratory failure: point prevalence survey of UK adult critical care. Mucoactive agents in acute respiratory failure: point prevalence survey of UK adult critical care, Birmingham. Forthcoming poster presentation. Intensive Care Society, 2019."}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2019-214355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T13:22:08Z","timestamp":1601990528000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2019-214355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":52,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,7,15]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/thoraxjnl-2019-214355"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2019-214355","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]}}}